Alcon buys majority stake in IPO-seeking cell therapy startup Aurion
The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over the direction of the company, which filed to go public in January.


The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over the direction of the company, which filed to go public in January.